Macular disease
Investors take note of Opthea’s potential
Australian biotech company Opthea has reported a solid cash position to further advance clinical trials of its lead drug candidate...
Read moreNew Australian study results add to Ozurdex?s efficacy
A significant Australian study into the effectiveness of Allergan’s Ozurdex implant as a treatment for Diabetic Macular Oedema (DME) has...
Read more
Shares soar as Australian AMD drug outperforms Lucentis
Melbourne-based biotech company Opthea has demonstrated that combination therapy involving its lead drug candidate OPT-302 is superior to standalone Lucentis...
Read more